Wugen to Present at the Innate Killer Summit 2022 – Yahoo Finance

ST. LOUIS & SAN DIEGO, March 24, 2022--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in a fireside chat and presentation at the Innate Killer Summit 2022 being held in San Diego, CA from Wednesday, March 30 Friday, April 1, 2022.

The details of Wugens fireside chat and presentation are as follows:

Format: Industry Leaders Fireside ChatPresenter: Dan Kemp, Ph.D., President and Chief Executive Officer, WugenDate & Time: Thursday, March 31, 2022 at 8:15 a.m. PT

Format: Presentation titled "Characterizing an Ideal NK Cell Phenotype Leveraging Assays to Indicate Therapeutic Benefit"Presenter: Ayman Kabakibi, Ph.D., Chief Operating Officer & Executive Vice President, Research & Development, WugenDate & Time: Thursday, March 31, 2022 at 11:30 a.m. PT

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit http://www.wugen.com.

Story continues

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005008/en/

Contacts

Investor Contact: Elsie Yau, Stern Investor Relations, Inc.212-698-8700elsie.yau@sternir.com

Go here to see the original:
Wugen to Present at the Innate Killer Summit 2022 - Yahoo Finance